Business

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

Demonstrated statistically significant reduction in cataplexy attacks compared to placebo

articleAxsome Therapeutics, Inc.December 3, 20193/company/axsome-therapeutics-inc/news/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-concert-phase-2-trial-in-narcolepsy

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

About this update from Axsome Therapeutics, Inc.

[{"type":"text","content":"Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p","length":114,"tagName":"div"}]

More updates from Axsome Therapeutics, Inc.